Despite a global slowdown in the development of new medical interventions, due to the scientific shift towards more complex biologic treatments, innovation in the U.S. has remained relatively steady thanks to strong financial incentives to invest in research and development (R&D).
In fact, the below chart may underrepresent American contributions to pharmacological breakthroughs in the past two decades as a result of U.S. corporations relocating their headquarters to Switzerland and the U.K. to take advantage of those countries’ lower corporate tax rates.
AAF provides data-driven insight to today’s defining domestic policy challenges, utilizes both in-house policy experts and a broad network of outside experts, and deploys modern communications approaches to express ideas and effectively engage policymakers, thought leaders, academics, media, and the general public.
To review the story’s accompany chart, click here.